These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

730 related articles for article (PubMed ID: 27774703)

  • 1. Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative.
    Coiro S; Girerd N; Rossignol P; Ferreira JP; Maggioni A; Pitt B; Tritto I; Ambrosio G; Dickstein K; Zannad F
    Eur J Heart Fail; 2017 Feb; 19(2):271-279. PubMed ID: 27774703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of β-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish nationwide cohort study.
    Andersson C; Mérie C; Jørgensen M; Gislason GH; Torp-Pedersen C; Overgaard C; Køber L; Jensen PF; Hlatky MA
    JAMA Intern Med; 2014 Mar; 174(3):336-44. PubMed ID: 24247428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of digitalis treatment with outcomes following myocardial infarction in patients with heart failure or evidence of left ventricular dysfunction: an analysis from the High-Risk Myocardial Infarction Database Initiative.
    Coiro S; Girerd N; Rossignol P; Bauersachs J; Pitt B; Fay R; Ambrosio G; Solomon SD; Dickstein K; Zannad F
    Clin Res Cardiol; 2017 Sep; 106(9):722-733. PubMed ID: 28455597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records.
    Quint JK; Herrett E; Bhaskaran K; Timmis A; Hemingway H; Wedzicha JA; Smeeth L
    BMJ; 2013 Nov; 347():f6650. PubMed ID: 24270505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.
    Bangalore S; Steg G; Deedwania P; Crowley K; Eagle KA; Goto S; Ohman EM; Cannon CP; Smith SC; Zeymer U; Hoffman EB; Messerli FH; Bhatt DL;
    JAMA; 2012 Oct; 308(13):1340-9. PubMed ID: 23032550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of β-blockers on all-cause mortality in patients with type 2 diabetes and coronary heart disease.
    Tsujimoto T; Sugiyama T; Kajio H
    Diabetes Obes Metab; 2017 Jun; 19(6):800-808. PubMed ID: 28094466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving outcomes in chronic obstructive pulmonary disease by taking beta-blockers after acute myocardial infarction: a nationwide observational study.
    Wang WH; Cheng CC; Mar GY; Wei KC; Huang WC; Liu CP
    Heart Vessels; 2019 Jul; 34(7):1158-1167. PubMed ID: 30680495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes in patients hospitalized for heart failure and chronic obstructive pulmonary disease: differences in clinical profile and treatment between 2002 and 2009.
    Staszewsky L; Cortesi L; Tettamanti M; Dal Bo GA; Fortino I; Bortolotti A; Merlino L; Latini R; Roncaglioni MC; Baviera M
    Eur J Heart Fail; 2016 Jul; 18(7):840-8. PubMed ID: 27098360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-blocker therapy is not associated with adverse outcomes in patients with pulmonary arterial hypertension: a propensity score analysis.
    Thenappan T; Roy SS; Duval S; Glassner-Kolmin C; Gomberg-Maitland M
    Circ Heart Fail; 2014 Nov; 7(6):903-10. PubMed ID: 25277998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-blocker use and mortality in COPD patients after myocardial infarction: a Swedish nationwide observational study.
    Andell P; Erlinge D; Smith JG; Sundström J; Lindahl B; James S; Koul S
    J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25854796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction.
    Dondo TB; Hall M; West RM; Jernberg T; Lindahl B; Bueno H; Danchin N; Deanfield JE; Hemingway H; Fox KAA; Timmis AD; Gale CP
    J Am Coll Cardiol; 2017 Jun; 69(22):2710-2720. PubMed ID: 28571635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of High Serum Bilirubin to Short-Term Mortality Following a Myocardial Infarction Complicated by Left Ventricular Systolic Dysfunction (from the High-Risk Myocardial Infarction Database Initiative).
    Frikha Z; Ferreira JP; Bozec E; McMurray JJV; Pitt B; Dickstein K; Rossignol P; Zannad F; Girerd N;
    Am J Cardiol; 2018 May; 121(9):1015-1020. PubMed ID: 29631805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The duration of beta-blocker therapy and outcomes in patients without heart failure or left ventricular systolic dysfunction after acute myocardial infarction: A multicenter prospective cohort study.
    Wen XS; Luo R; Liu J; Liu ZQ; Zhang HW; Hu WW; Duan Q; Qin S; Xiao J; Zhang DY
    Clin Cardiol; 2022 May; 45(5):509-518. PubMed ID: 35246866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-Blockers in Atrial Fibrillation Patients With or Without Heart Failure: Association With Mortality in a Nationwide Cohort Study.
    Nielsen PB; Larsen TB; Gorst-Rasmussen A; Skjøth F; Lip GY
    Circ Heart Fail; 2016 Feb; 9(2):e002597. PubMed ID: 26823497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence of potential bias in a comparison of β blockers and calcium channel blockers in patients with chronic obstructive pulmonary disease and acute coronary syndrome: results of a multinational study.
    Dong YH; Alcusky M; Maio V; Liu J; Liu M; Wu LC; Chang CH; Lai MS; Gagne JJ
    BMJ Open; 2017 Mar; 7(3):e012997. PubMed ID: 28363921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship Between β-Blocker Therapy at Discharge and Clinical Outcomes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Li C; Sun Y; Shen X; Yu T; Li Q; Ruan G; Zhang L; Huang Q; Zhuang H; Huang J; Ni L; Wang L; Jiang J; Wang Y; Wang DW
    J Am Heart Assoc; 2016 Nov; 5(11):. PubMed ID: 27852588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative.
    von Lueder TG; Girerd N; Atar D; Agewall S; Lamiral Z; Kanbay M; Pitt B; Dickstein K; Zannad F; Rossignol P;
    Eur J Heart Fail; 2015 Nov; 17(11):1144-51. PubMed ID: 26424212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators.
    Vantrimpont P; Rouleau JL; Wun CC; Ciampi A; Klein M; Sussex B; Arnold JM; Moyé L; Pfeffer M
    J Am Coll Cardiol; 1997 Feb; 29(2):229-36. PubMed ID: 9014971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease.
    Kubota Y; Asai K; Furuse E; Nakamura S; Murai K; Tsukada YT; Shimizu W
    Int J Chron Obstruct Pulmon Dis; 2015; 10():515-23. PubMed ID: 25784798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
    Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.